Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

FDA panel recommends COVID vaccines for little kids, but questions remain about where they’ll be available

CHICAGO — Mary MacMillan is eager to get her 2-year-old son vaccinated against COVID-19, once vaccines are authorized for young kids. But she has a lot of questions about how to get the shots.

Chicago Tribune

America's FDA panel backs Moderna and Pfizer COVID-19 vaccines for children under five. Here's what that means

Advisors to US federal regulators are backing two COVID-19 vaccines for children as young as six months old, with the final decision to be watched closely by Australian health officials, along with parents eager to put pandemic concerns behind them.

ABC News

Moderna’s COVID shot for youngest children gets FDA panel’s support

Moderna Inc.’s COVID-19 vaccine for infants and toddlers won the support of a panel of U.S. regulatory advisers, putting parents one step closer to being able to protect their youngest against COVID-19 for the first time.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA just authorized Covid-19 vaccines for kids under 5. Here’s what parents need to know

An outside panel of experts for the FDA recommended both the Moderna and Pfizer vaccine for kids under 5. Shortly after, the FDA granted a EUA.

Inverse

FDA advisers weigh COVID-19 shots for babies, young children

U.S. government advisers met Wednesday to decide whether to endorse COVID-19 shots for the youngest children, moving the nation closer to vaccinations for all ages

The Independent UK

$100 Invested In This Stock 10 Years Ago Would Be Worth $3,600 Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 10 years by 32.14% on an annualized basis producing an average annual return of 42.94%. Currently, Moderna has a market capitalization of $49.53 billion.

Benzinga

What's hot in life sciences? Bio International Convention looks at what's next as pandemic recedes

It's no secret that during the COVID-19 pandemic, the global life sciences industry shined. It ramped up development of everything from diagnostic tests to new vaccines — including two based on previously unproven messenger RNA technology —all within months instead of years.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

FDA advisers consider Moderna's COVID shots for older kids

A government advisory panel is meeting to decide whether to recommend a second brand of COVID-19 vaccine for school-age children and teens

The Independent UK

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

The youngest Americans may finally get their COVID shots

Regulators will evaluate both Pfizer-BioNTech and Moderna shots this week.

Axios

Pfizer COVID shot works, safe for youngest kids, FDA says

U.S. Food and Drug Administration staff said that Pfizer Inc.’s COVID-19 shot was effective for kids ages 4 and under with no new safety concerns, in a report released ahead of a key meeting of FDA advisers later this week.

Tribune News Service

US: Pfizer COVID-19 appears effective for kids under 5

A review by federal health officials says that Pfizer's COVID-19 vaccine appears safe and effective for children under 5, the only group not currently eligible for vaccination

The Independent UK

Research on a deadly bacteria might be a COVID-19 vaccine gamechanger

The Covid-19 pandemic, being truly global, created the demand for vaccines, such as the now-familiar ones from Pfizer, Moderna and AstraZeneca.

Inverse

Marathon US hearings to decide fate of COVID shots for tots

Next week brings a marathon of hearings as the U.S. decides whether to open COVID-19 vaccinations to kids under 5

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Moderna Stock Is Moving Lower Today

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vacci

Benzinga

US Schedules Covid-19 Vaccines For Children Below Five Years

The U.S. government is preparing to launch vaccines for children below five in conjunction with educational and outreach efforts, pending approval by federal regulators, the Wall Street Journal reports. The government looks to provide ten million initial doses as the virus spreads nationwide, leaving the parents anxious. The vaccinations could begin…

Benzinga

Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker

Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc (NASDAQ: MRNA) after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide strong

The Guardian - UK

Trials of new COVID vaccine raise hopes of once-a-year booster

Moderna shot is said to produce eightfold increase in antibody levels against Omicron in first four weeks

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Moderna vaccine trial raises hopes of yearly Covid booster

People who received vaccine showed significant jump in antibody levels compared to original Moderna jab

Tribune News Service

Moderna’s omicron-targeted shot bolsters antibodies in trial

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Benzinga

Moderna's Updated COVID-19 Shot Boosts Omicron Protection

Moderna Inc (NASDAQ: MRNA) has

Axios

Moderna booster update for Omicron variant could be available late summer

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

Benzinga

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

The Independent UK

Moderna announces promising results from next-generation Covid vaccine trials

Experts hope the newer jabs could protect against a wider range of variants.

WEKU

Moderna says its new vaccine booster shows 'superior' response to omicron

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

1 … 21 22 23 24

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

323 stories

Pfizer Inc

312 stories

Chicago Public Schools

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.